Harvind S Chahal, MD
Dermatology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 2
- Since medical school
- 9 years
- Stanford University School of Medicine, 2017
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chahal’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A159061 · Current
Licensed to practise in California · since 2018 · expires 2026-10-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Dermatology - Dermatology
Original Medicare doctor bills
$205,984
Medicare paid this office $205,984 for 745 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 320 | $43,364 | $107 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 26 | $30,341 | $86 |
| Short return visit (20+ min) | 249 | $22,620 | $76 |
| New patient visit (45+ min) | 120 | $17,254 | $144 |
| Destruction of precancer skin growth, 15 or more growths | 102 | $15,361 | $128 |
See all 14 services
| Return visit (30+ min) | 320 | $43,364 | $107 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 26 | $30,341 | $86 |
| Short return visit (20+ min) | 249 | $22,620 | $76 |
| New patient visit (45+ min) | 120 | $17,254 | $144 |
| Destruction of precancer skin growth, 15 or more growths | 102 | $15,361 | $128 |
| New patient visit (30+ min) | 126 | $11,893 | $94 |
| Destruction of precancer skin growth, 1 growth | 155 | $10,364 | $59 |
| Biopsy of related skin growth, first growth | 112 | $10,255 | $85 |
| Destruction of skin growth, 1-14 growths | 85 | $9,233 | $98 |
| Destruction of precancer skin growth, 2-14 growths | 131 | $5,027 | $6 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 85 | $1,804 | $15 |
| Biopsy of related skin growth, each additional growth | 24 | $1,593 | $51 |
| Punch biopsy, first skin growth | 14 | $1,561 | $111 |
| Short return visit | 15 | $673 | $45 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 414 | More than 85% of doctors who do this |
| Skin biopsy | 88 | More than 74% of doctors who do this |
Procedures year by year
| Procedure | 2022 | 2023 | 2024 |
|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 84 | 164 | 781 |
| Destruction of precancer skin growth, 1 growth | 17 | 48 | 175 |
| Destruction of precancer skin growth, 15 or more growths | – | 99 | 120 |
| Biopsy of related skin growth, first growth | 11 | 49 | 120 |
| Destruction of skin growth, 1-14 growths | – | 52 | 94 |
| Biopsy of related skin growth, each additional growth | – | – | 31 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
745 Original Medicare patients in 2024. Average age 76 · Under 65 5% · 85 and older 16% · Women 51% · Also on Medicaid 16% · Health risk score 1.06. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 65% · Diabetes 24% · Chronic kidney disease 19% · Coronary heart disease 17% · Cancer 15% · Atrial fibrillation 15% · Depression 14% · Heart failure 11% · COPD 8% · Stroke 6% · Dementia 5%.
The office billed $665,745, Medicare allowed $292,137 and paid $205,984; for 2,886 services of 57 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 745 | 2,886 | 76 | 1.06 | $665,745 | $205,984 |
| 2023 | 357 | 1,277 | 75 | 0.99 | $266,386 | $130,353 |
| 2022 | 89 | 248 | 76 | 0.94 | $35,679 | $21,055 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 26 | $30,399 | $94 |
| Return visit (30+ min) | 194 | $29,439 | $119 |
| Destruction of precancer skin growth, 15 or more growths | 87 | $16,858 | $170 |
| Short return visit (20+ min) | 111 | $10,628 | $85 |
| New patient visit (45+ min) | 49 | $7,087 | $145 |
| Destruction of skin growth, 1-14 growths | 48 | $5,951 | $114 |
| Biopsy of related skin growth, first growth | 47 | $4,859 | $99 |
| New patient visit (30+ min) | 43 | $4,199 | $98 |
| Destruction of precancer skin growth, 1 growth | 43 | $2,922 | $61 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $1,147 | $7 |
2022: 6 services
| Return visit (30+ min) | 31 | $3,902 | $111 |
| New patient visit (45+ min) | 20 | $2,370 | $118 |
| Short return visit (20+ min) | 22 | $2,040 | $82 |
| Biopsy of related skin growth, first growth | 11 | $1,088 | $99 |
| Destruction of precancer skin growth, 1 growth | 17 | $992 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 15 | $585 | $7 |
Medicaid work
$114 in 2024
Medicaid paid $114 for 13 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 13 | $114 |
| 2024 | 13 | 1 | 13 | $114 |
| 2023 | 93 | 2 | 23 | $1,964 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 80 | $1,688 |
| New patient visit (45+ min) | 13 | $276 |
Drugs they prescribed that Part D paid
$320,077
Pharmacies billed $320,077 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 848) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
751 generic and 97 brand-name prescriptions · $320,077 in drug cost · 38 antibiotic prescriptions to 26 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Otezla | 16 | $49,862 | $3,116 |
| Dupixent | 12 | $49,289 | $4,107 |
| Dupixent | 13 | $49,267 | $3,790 |
| Clobetasol Propionate | 154 | $5,418 | $35 |
| Tacrolimus | 44 | $4,636 | $105 |
See all 16 drugs
| Otezla | 16 | $49,862 | $3,116 |
| Dupixent | 12 | $49,289 | $4,107 |
| Dupixent | 13 | $49,267 | $3,790 |
| Clobetasol Propionate | 154 | $5,418 | $35 |
| Tacrolimus | 44 | $4,636 | $105 |
| Betamethasone Diprop Augmented | 67 | $2,966 | $44 |
| Triamcinolone Acetonide | 128 | $1,642 | $13 |
| Metronidazole | 21 | $1,505 | $72 |
| Doxycycline Hyclate | 22 | $1,329 | $60 |
| Ketoconazole | 75 | $1,165 | $16 |
| Fluocinonide | 21 | $831 | $40 |
| Minoxidil | 25 | $403 | $16 |
| Mupirocin | 23 | $301 | $13 |
| Hydrocortisone | 56 | $265 | $5 |
| Valacyclovir | 15 | $185 | $12 |
| Mometasone Furoate | 13 | $155 | $12 |
Year by year
| 2024 | 848 | 366 | 0% (0) | 11% | $320,077 |
| 2023 | 1,671 | 575 | 0% (0) | 9% | $668,382 |
| 2022 | 688 | 328 | 0% (0) | 5% | $100,600 |
| 2021 | 58 | 34 | 0% (0) | None | $2,843 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Dupixent | 42 | $157,861 | $3,759 |
| Otezla | 11 | $48,099 | $4,373 |
| Clobetasol Propionate | 280 | $23,385 | $84 |
| Tacrolimus | 82 | $13,819 | $169 |
| Betamethasone Diprop Augmented | 153 | $6,932 | $45 |
| Triamcinolone Acetonide | 312 | $5,101 | $16 |
| Calcipotriene | 14 | $3,730 | $266 |
| Doxycycline Hyclate | 34 | $3,359 | $99 |
| Metronidazole | 50 | $3,165 | $63 |
| Tretinoin | 15 | $2,838 | $189 |
| Ketoconazole | 122 | $2,817 | $23 |
| Fluocinonide | 45 | $2,741 | $61 |
| Halobetasol Propionate | 14 | $1,828 | $131 |
| Ciclopirox | 26 | $1,221 | $47 |
| Methotrexate | 14 | $971 | $69 |
| Hydrocortisone | 139 | $768 | $6 |
| Econazole Nitrate | 24 | $631 | $26 |
| Doxepin | 12 | $325 | $27 |
| Mometasone Furoate | 11 | $323 | $29 |
| Mupirocin | 32 | $276 | $9 |
| Cephalexin | 29 | $262 | $9 |
| Minoxidil | 15 | $237 | $16 |
| Prednisone | 21 | $134 | $6 |
2022: 11 drugs
| Clobetasol Propionate | 97 | $8,501 | $88 |
| Tacrolimus | 29 | $5,165 | $178 |
| Betamethasone Diprop Augmented | 69 | $4,852 | $70 |
| Triamcinolone Acetonide | 140 | $2,472 | $18 |
| Fluocinonide | 31 | $1,805 | $58 |
| Ketoconazole | 61 | $1,656 | $27 |
| Metronidazole | 17 | $1,236 | $73 |
| Doxycycline Hyclate | 20 | $980 | $49 |
| Hydrocortisone | 50 | $309 | $6 |
| Mupirocin | 31 | $259 | $8 |
| Hydroxyzine | 13 | $204 | $16 |
Money from drug and device companies
$971 in 2025
| 2025 | 6 | 8 | None | $971 |
| 2024 | 9 | 17 | None | $891 |
| 2023 | 15 | 135 | None | $3,230 |
| 2022 | 14 | 76 | None | $2,452 |
| 2021 | 4 | 25 | None | $888 |
| 2020 | 1 | 1 | None | $99 |
| 2019 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Galderma Laboratories L.P. | Nemluvio | $331 | 2 payments
|
| LEO Pharma | Anzupgo | $145 | 1 payment
|
| Genzyme | Dupixent | $142 | 2 payments
|
| Incyte | Opzelura | $123 | 1 payment
|
| Lilly USA | Ebglyss | $121 | 1 payment
|
| Abbvie | Skyrizi | $109 | 1 payment
|
See all 8 published payments
| Galderma Laboratories L.P. | Meals · 2025-12-10 | Nemluvio | $142 |
| LEO Pharma | Meals · 2025-10-03 | Anzupgo | $145 |
| Genzyme | Meals · 2025-09-24 | Dupixent | $107 |
| Genzyme | Meals · 2025-09-16 | None | $35 |
| Incyte | Meals · 2025-05-28 | Opzelura | $123 |
| Abbvie | Meals · 2025-03-19 | Skyrizi | $109 |
| Lilly USA | Meals · 2025-02-26 | Ebglyss | $121 |
| Galderma Laboratories L.P. | Meals · 2025-01-29 | Nemluvio | $189 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $891
| Abbvie | Skyrizi | $313 | 4 payments
|
| Genzyme | Dupixent | $155 | 2 payments
|
| Janssen Biotech | Tremfya | $154 | 3 payments
|
| Incyte | Opzelura | $111 | 1 payment
|
| Pfizer | Cibinqo | $40 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $38 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $29 | 1 payment
|
| Novartis Pharmaceuticals | Cosentyx | $28 | 1 payment
|
| Dermavant Sciences | Vtama | $24 | 1 payment
|
2023: $3,230
| AbbVie | Skyrizi | $767 | 24 payments
|
| Lilly USA | Taltz | $374 | 14 payments
|
| Incyte | Opzelura | $362 | 11 payments
|
| Janssen Biotech | Tremfya | $354 | 15 payments
|
| Regeneron Healthcare Solutions | Dupixent | $291 | 11 payments
|
| Genzyme | Dupixent | $245 | 6 payments
|
| Pfizer | Cibinqo | $208 | 11 payments
|
| LEO Pharma | Adbry | $205 | 21 payments
|
| Dermavant Sciences | Vtama | $159 | 10 payments
|
| Sun Pharmaceutical Industries | Ilumya | $96 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $87 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Spevigo | $26 | 1 payment
|
| Novartis Pharmaceuticals | Xolair | $19 | 1 payment
|
| Arcutis Biotherapeutics | None | $18 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $17 | 1 payment
|
2022: $2,452
| Regeneron Healthcare Solutions | Dupixent | $703 | 14 payments
|
| Abbvie | Skyrizi | $612 | 24 payments
|
| Sun Pharmaceutical Industries | Ilumya | $270 | 5 payments
|
| Genzyme | Dupixent | $183 | 8 payments
|
| Pfizer | Cibinqo | $160 | 5 payments
|
| Incyte | Opzelura | $155 | 4 payments
|
| Lilly USA | Taltz | $82 | 3 payments
|
| Janssen Biotech | Remicade | $78 | 4 payments
|
| Ucb | Cimzia | $61 | 2 payments
|
| Novartis Pharmaceuticals | Cosentyx | $50 | 2 payments
|
| Amgen | Otezla | $28 | 1 payment
|
| LEO Pharma | Adbry | $26 | 2 payments
|
| Journey Medical | Qbrexza | $23 | 1 payment
|
| Dermavant Sciences | Vtama | $22 | 1 payment
|
2021: $888
| Genzyme | Libtayo | $337 | 7 payments
|
| Regeneron Healthcare Solutions | Dupixent | $296 | 5 payments
|
| AbbVie | Humira | $220 | 11 payments
|
| Sun Pharmaceutical Industries | Ilumya | $36 | 2 payments
|
2020: $99
| AbbVie | Skyrizi | $99 | 1 payment
|
2019: $125
| Celgene | Otezla | $125 | 1 payment
|
Professional record
- NPI
- 1508392168
- Licence
- CA A159061California A159061: Current · expires 2026-10-31
- Trained
- Stanford University School of Medicine, 2017 · 9 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 325 Distel Cir Ste 380, Los Altos, CA, 94022
- NPI first listed
- 2017-05-02
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 12 Camino Encinas, Orinda, CA, 94563